Missed Opportunities to Initiate Oral Anticoagulant in Atrial Fibrillation: Insights from Australian Acute Coronary Syndrome Registries

摘要: Background Many patients with atrial fibrillation (AF) do not receive oral anticoagulant (OAC) therapy. The aims of this study were to 1) document receipt OAC among a history AF admitted an acute coronary syndrome (ACS); and 2) determine whether hospital admission was associated improvement in prescription Methods Using Australian data from the Cooperative National Registry Acute Coronary Care, Guideline Adherence Clinical Events (CONCORDANCE) Global (GRACE) registries, 1,479 presenting ACS separated into two groups: aspirin monotherapy/no therapy (No OAC) or ± (OAC). characteristics in-hospital treatments outcomes compared. Results Of patients, 532 (36%) presented on remainder receiving antiplatelet (n=580 [39%]) no antithrombotic (n=367 [25%]). Treatment prior presentation increased during 18 years (27% 56%, p=0.0002). Ninety-five per cent (95%) group had CHA2DS2-VA score >1 vs 88% No (p Conclusion In AF, has improved over time but remains suboptimal. There is minimal escalation provision care, indicating missed opportunities address evidence practice gap.